163 related articles for article (PubMed ID: 17175307)
1. Sirolimus attenuates the rate of progression of early chronic allograft nephropathy.
Sumethkul V; Changsirikulchai S; Lothuvachai T; Chalermsanyakorn P
Transplant Proc; 2006 Dec; 38(10):3470-2. PubMed ID: 17175307
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy.
Gonzalez Molina M; Seron D; Garcia del Moral R; Carrera M; Sola E; Jesus Alferez M; Gomez Ullate P; Capdevila L; Gentil MA
Transplantation; 2004 Jan; 77(2):215-20. PubMed ID: 14742984
[TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003-2011.
Ignjatović L; Hrvacević R; Jovanović D; Kovacević Z; Vavić N; Rabrenović V; Tomić A; Aleksić P; Drasković-Pavlović B; Dujić A; Karan Z; Maksić D
Vojnosanit Pregl; 2013 Sep; 70(9):848-53. PubMed ID: 24266313
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy.
Henne T; Latta K; Strehlau J; Pape L; Ehrich JH; Offner G
Transplantation; 2003 Nov; 76(9):1326-30. PubMed ID: 14627911
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
7. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
[TBL] [Abstract][Full Text] [Related]
8. Chronic allograft nephropathy score before sirolimus rescue predicts allograft function in renal transplant patients.
Basu A; Falcone JL; Tan HP; Hassan D; Dvorchik I; Bahri K; Thai N; Randhawa PS; Marcos A; Starzl TE; Shapiro R
Transplant Proc; 2007; 39(1):94-8. PubMed ID: 17275482
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy.
Stoves J; Newstead CG; Baczkowski AJ; Owens G; Paraoan M; Hammad AQ
Nephrol Dial Transplant; 2004 Aug; 19(8):2113-20. PubMed ID: 15161956
[TBL] [Abstract][Full Text] [Related]
10. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience.
Saber LT; Ikeda MY; Almeida JM
Transplant Proc; 2007 Dec; 39(10):3098-100. PubMed ID: 18089330
[TBL] [Abstract][Full Text] [Related]
11. The effect of sirolimus in the development of chronic allograft nephropathy.
Gürkan A; Kaçar S; Erdoğdu U; Varilsüha C; Kandemir G; Karaca C; Akman F
Transplant Proc; 2008; 40(1):114-6. PubMed ID: 18261561
[TBL] [Abstract][Full Text] [Related]
12. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
[TBL] [Abstract][Full Text] [Related]
14. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
[TBL] [Abstract][Full Text] [Related]
15. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
Tsai MK; Lee CY; Hu RH; Lee PH
J Formos Med Assoc; 2007 May; 106(5):372-9. PubMed ID: 17561472
[TBL] [Abstract][Full Text] [Related]
16. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
17. Conversion from cyclosporine to sirolimus in stable renal transplant recipients.
Sennesael JJ; Bosmans JL; Bogers JP; Verbeelen D; Verpooten GA
Transplantation; 2005 Dec; 80(11):1578-85. PubMed ID: 16371929
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus in chronic allograft nephropathy in pediatric recipients.
Ibáñez JP; Monteverde ML; Diaz MA; Goldberg J; Turconi AF
Pediatr Transplant; 2007 Nov; 11(7):777-80. PubMed ID: 17910656
[TBL] [Abstract][Full Text] [Related]
19. Effect of mycophenolate mofetil on kidney graft function and body weight in patients with chronic allograft nephropathy.
Grebe SO; Mueller TF; Troeltsch M; Ebel H; Lange H
Transplant Proc; 2004 Dec; 36(10):2974-8. PubMed ID: 15686673
[TBL] [Abstract][Full Text] [Related]
20. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
